SQZ Biotechnologies Company
SQZ was delisted on the 3rd of July, 2023.
53 hedge funds and large institutions have $47.1M invested in SQZ Biotechnologies Company in 2022 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 16 closing their positions.
13% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 16
0% more funds holding
Funds holding: 53 → 53 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
27% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 15
38% less capital invested
Capital invested by funds: $76.6M → $47.1M (-$29.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
+$1.55M |
| 2 |
Stifel Financial
St. Louis,
Missouri
|
+$1.04M |
| 3 |
E
Ergoteles
New York
|
+$375K |
| 4 |
Millennium Management
New York
|
+$332K |
| 5 |
RC
RBF Capital
San Francisco,
California
|
+$288K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.94M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.07M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$686K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$542K |
| 5 |
AI
Alphabet Inc
Mountain View,
California
|
-$500K |
SQZ Hedge Fund Activity: Q2 2022 in Review
53 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in SQZ Biotechnologies Company (SQZ) for Q2 2022, worth a combined $47.1M — down 38% from $76.6M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new SQZ positions and 16 closed out — a net gain of 2 holders — while 11 added to existing stakes and 15 trimmed.
The largest buyer was Laurion Capital Management, opening a new position worth an estimated $1.55M. The largest seller was BlackRock, cutting an estimated $3.94M.
- 53 institutional investors held SQZ Biotechnologies Company (SQZ) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $47.1M of SQZ Biotechnologies Company stock for Q2 2022, down 38% quarter-over-quarter.
- 18 funds opened new SQZ Biotechnologies Company positions in Q2 2022 and 16 closed out, a net change of +2 holders.
- The largest SQZ Biotechnologies Company buyer in Q2 2022 was Laurion Capital Management, an estimated $1.55M added.
- The largest SQZ Biotechnologies Company seller in Q2 2022 was BlackRock, an estimated $3.94M sold.
Based on aggregated 13F filings for Q2 2022.